Nuvalent, Inc.
Nuvalent, Inc. (NUVL) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Nuvalent, Inc. (NUVL), featuring income statements, balance sheets, and cash flow data.
Nuvalent, Inc. (NUVL) Income Statement & Financial Overview
Analyze Nuvalent, Inc.’s NUVL earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $74.42M | $69.42M | $60.55M | $49.17M |
| SG&A Expenses | $20.39M | $16.88M | $15.78M | $15.98M |
| Operating Expenses | $94.81M | $86.30M | $76.33M | $65.15M |
| Total Costs & Expenses | $94.81M | $86.30M | $76.33M | $65.15M |
| Interest Income | $11.82M | $13.05M | $8.63M | $8.15M |
| Interest Expense | $11.82M | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | -$52.59M | $0.00 | $0.00 |
| EBITDA | -$94.81M | -$86.30M | -$76.33M | -$65.15M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$94.81M | -$86.30M | -$76.33M | -$65.15M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $10.39M | $11.71M | -$7.97M | $8.15M |
| Income Before Tax | -$84.42M | -$74.59M | -$84.31M | -$57.00M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $157000.00 | $171000.00 | $40000.00 | $170000.00 |
| Net Income | -$84.58M | -$74.76M | -$84.34M | -$57.17M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$1.18 | -$1.05 | -$1.28 | -$0.88 |
| Diluted EPS | -$1.18 | -$1.05 | -$1.28 | -$0.88 |
| Weighted Avg Shares Outstanding | $71.61M | $71.16M | $65.68M | $64.61M |
| Weighted Avg Shares Outstanding (Diluted) | $71.61M | $71.16M | $65.68M | $64.61M |
Over the past four quarters, Nuvalent, Inc. demonstrated steady revenue growth, increasing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Operating income reached -$94.81M in Q1 2025, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$94.81M, reflecting operational efficiency. Net income dropped to -$84.58M, with EPS at -$1.18. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan